Odinachi Oguh, MD, movement disorder specialist at the Cleveland Clinic Lou Ruvo Center for Brain Health, shares clinical perspectives on biomarkers, aging, non-motor symptoms, and prodromal disease from the 2026 MDS Congress.
News|Videos|March 2, 2022
AUPN Leadership Minute Episode 19: Happy Faculty-Happy Life: Improving Faculty Satisfaction
Episode 19 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University; and Susan Matulevicius, MD, MSCS, of UT Southwestern Medical Center. [WATCH TIME: 4 minutes]
Advertisement
WATCH TIME: 4 minutes
AUPN's Leadership Minute is a brief, highly focused summary of practical advice for Chairs, Program Directors and other leaders in academic neurology, available as both mini-podcasts and in short form videos.
The goal of this program is to provide relevant and useful information in a modicum of time, designed to fit seamlessly into our very busy schedules.
A system-level commitment to wellness is essential to allowing faculty to perform at their best. By valuing faculty for their contributions, providing support and connection, making sure all voices are heard, and involving faculty in decisions and change, faculty can achieve their full potential while also advancing institutional missions.
Advertisement
Related to this article
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.
GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.
In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.
At a NeurologyLive Clinical Forum in New York, Mary Ann Piccone, MD, of Holy Name Medical Center, led a wide-ranging discussion among MS specialists on the limits of current high-efficacy therapies, the pipeline of emerging agents, and the gap between physician and patient treatment priorities.
A study of deceased former NFL players estimated that nearly 75% had CTE neuropathology, while a phase 3 trial is evaluating whether F-18 FNT-PET imaging could help identify disease-associated patterns in living patients.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Investigates Confirmed Insertional Oncogenesis With Spinal Muscular Atrophy Gene Therapy
2
New York Forum Tackles Unmet Needs in Multiple Sclerosis Care
3
FDA Approves Factor XIa Inhibitor Asundexian for Secondary Stroke Prevention
4
New CTE Prevalence Estimate Underscores Push for Diagnosis Living Patients
5